Short answer
Twist Bioscience Corp (TWST) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.2). Equity offering expanded to 3,593,750 shares at $96.00 per share, including fully exercised 468,750-share option.
Twist Bioscience Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Equity offering expanded to 3,593,750 shares at $96.00 per share, including fully exercised 468,750-share option
- Approximately $327.1 million net proceeds expected after underwriting discounts and offering expenses
- Capital raise increases liquidity for corporate purposes while diluting existing shareholders
- Offering expected to close around August 6, 2026, subject to customary conditions
Item 7.01 · Regulation FD Disclosure
- Proposed equity offering increased from $250.0 million to an upsized $300.0 million
- Pricing indicates stronger-than-anticipated demand, but creates potential shareholder dilution
- Investors should review Exhibit 99.2 for offering price, share count, and use of proceeds
Item EX-99.1 · Exhibit EX-99.2
- Proposed $250.0M underwritten common-stock offering, creating dilution risk for existing shareholders
- Additional underwriter option for up to $37.5M, potentially increasing total issuance
- Proceeds targeted at R&D, manufacturing-capacity expansion, product offerings, working capital, and general corporate purposes
- Offering remains subject to market conditions, with no assurance of completion or final terms
- Equity raise supports growth investment while increasing near-term reliance on shareholder capital
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Twist Bioscience Corp 8-K filings
Get the next TWST 8-K as it lands
Follow TWST for push alerts, or ask the research agent what this filing means.